BE2016C014I2 - - Google Patents

Download PDF

Info

Publication number: BE2016C014I2
Authority: BE; Belgium

Application number

BE2016C014C

Other languages

French (fr)

Original Assignee

Onyx Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-15

Filing date

2016-04-21

Publication date

2024-10-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-04-21 Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc

2024-10-09 Publication of BE2016C014I2 publication Critical patent/BE2016C014I2/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Plant Substances (AREA)

BE2016C014C 2004-04-15 2016-04-21 BE2016C014I2 (zh)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date
US56234004P	2004-04-15	2004-04-15
US56909604P	2004-05-07	2004-05-07
US59940104P	2004-08-06	2004-08-06
US61000104P	2004-09-14	2004-09-14
US61015904P	2004-09-14	2004-09-14
US61000204P	2004-09-14	2004-09-14
US62057304P	2004-10-20	2004-10-20

Publications (1)

Publication Number	Publication Date
BE2016C014I2 true BE2016C014I2 (zh)	2024-10-09

Family

ID=34965899

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2016C014C BE2016C014I2 (zh)	2004-04-15	2016-04-21

Country Status (17)

Country	Link
US (9)	US8129346B2 (zh)
EP (1)	EP1745064B1 (zh)
JP (3)	JP5616569B2 (zh)
CN (2)	CN103554222A (zh)
AT (1)	ATE494298T1 (zh)
AU (1)	AU2005238445B2 (zh)
BE (1)	BE2016C014I2 (zh)
BR (1)	BRPI0509879A (zh)
CA (1)	CA2562411A1 (zh)
CY (1)	CY1117244T1 (zh)
DE (1)	DE602005025750D1 (zh)
DK (1)	DK1745064T3 (zh)
IL (3)	IL178400A (zh)
PL (1)	PL1745064T3 (zh)
PT (1)	PT1745064E (zh)
SG (2)	SG152239A1 (zh)
WO (1)	WO2005105827A2 (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005238445B2 (en) *	2004-04-15	2012-05-03	Onyx Therapeutics, Inc.	Compounds for enzyme inhibition
US8198270B2 (en) *	2004-04-15	2012-06-12	Onyx Therapeutics, Inc.	Compounds for proteasome enzyme inhibition
AU2012203602B2 (en) *	2004-04-15	2015-08-27	Onyx Therapeutics, Inc.	Compounds for proteasome enzyme inhibition
US7232818B2 (en) *	2004-04-15	2007-06-19	Proteolix, Inc.	Compounds for enzyme inhibition
JP5108509B2 (ja)	2004-05-10	2012-12-26	プロテオリックス，インコーポレイテッド	酵素阻害のための化合物
AU2005313975B2 (en) *	2004-12-07	2012-09-06	Onyx Therapeutics, Inc.	Composition for proteasome inhibition
JP5436860B2 (ja)	2005-11-09	2014-03-05	オニキスセラピューティクス，インク．	酵素阻害のための化合物
WO2007149512A2 (en)	2006-06-19	2007-12-27	Proteolix, Inc.	Peptide epoxyketones for pr0teas0me inhibition
MY173938A (en)	2007-10-04	2020-02-27	Onyx Therapeutics Inc	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2009308516B2 (en)	2008-10-21	2016-08-25	Onyx Therapeutics, Inc.	Combination therapy with peptide epoxyketones
ES2634431T3 (es) *	2009-03-16	2017-09-27	The Governing Council Of The University Of Toronto	Moléculas de aminoácidos cíclicos y procedimientos de preparación de las mismas
AR075899A1 (es)	2009-03-20	2011-05-04	Onyx Therapeutics Inc	Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
GB0914883D0 (en)	2009-08-26	2009-09-30	Univ Belfast	Compound
US8853147B2 (en)	2009-11-13	2014-10-07	Onyx Therapeutics, Inc.	Use of peptide epoxyketones for metastasis suppression
BR112012022060A2 (pt)	2010-03-01	2018-05-08	Onyx Therapeutics Inc	composto para a inibição de imunoproteassoma
EP2555621A4 (en)	2010-04-07	2014-07-02	Onyx Therapeutics Inc	CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
SG10201609318UA (en) *	2012-05-08	2016-12-29	Onyx Therapeutics Inc	Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
US20140105921A1 (en)	2012-07-09	2014-04-17	Onyx Therapeutics, Inc.	Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
US10076384B2 (en)	2013-03-08	2018-09-18	Symple Surgical, Inc.	Balloon catheter apparatus with microwave emitter
PT2968555T (pt)	2013-03-13	2020-07-14	Univ California	Composições compreendendo anticorpos anti-cd38 e carfilzomib
JP6851826B2 (ja)	2013-07-19	2021-03-31	オニキスセラピューティクス，インク．ＯｎｙｘＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	がんの治療のためのｐｉｍキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤
CN103360348B (zh) *	2013-07-25	2015-06-24	苏州鹏旭医药科技有限公司	一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
CN105518019A (zh) *	2013-09-06	2016-04-20	桑多斯股份公司	肽环氧基酮的合成
WO2015032622A1 (en) *	2013-09-06	2015-03-12	Sandoz Ag	Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib
CN104710507B (zh) *	2013-12-11	2018-08-14	深圳翰宇药业股份有限公司	一种卡非佐米的制备方法
WO2015121769A1 (en)	2014-02-13	2015-08-20	Ranbaxy Laboratories Limited	Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
EP3166933B1 (en) *	2014-07-14	2018-08-01	Centrax International Inc.	Epoxyketone compounds for enzyme inhibition
US10329325B2 (en)	2014-09-24	2019-06-25	Biophore India Pharmaceuticals Pvt. Ltd	Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
WO2016069479A1 (en)	2014-10-27	2016-05-06	Apicore Us Llc	Methods of making carfilzomib and intermediates thereof
CN107548400A (zh)	2014-12-02	2018-01-05	费森尤斯卡比肿瘤学有限公司	卡非佐米的纯化方法
EP3240575A4 (en)	2014-12-31	2018-07-25	Dr. Reddy's Laboratories Ltd.	Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
WO2016116882A2 (en) *	2015-01-23	2016-07-28	Leiutis Pharmaceuticals Pvt Ltd	Novel compositions of carfilzomib
US10544189B2 (en) *	2015-04-22	2020-01-28	Msn Laboratories Private Limited	Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide
WO2016170489A1 (en)	2015-04-24	2016-10-27	Fresenius Kabi Oncology Ltd.	Pharmaceutical compositions of proteasome inhibitor
ES2888800T3 (es)	2015-05-21	2022-01-07	Laurus Labs Ltd	Procedimiento mejorado para la preparación de carfilzomib o sales farmacéuticamente aceptables del mismo
US11072616B2 (en)	2015-11-11	2021-07-27	Universite De Montreal	Cyclic peptides targeting alpha-4-beta-7 integrin
WO2018024645A1 (en)	2016-08-02	2018-02-08	Synthon B.V.	Process for making carfilzomib
WO2018051237A1 (en)	2016-09-14	2018-03-22	Fresenius Kabi Oncology Limited	A process for purification of carfilzomib intermediate
DK3538542T3 (da)	2016-11-11	2021-10-11	Zealand Pharma As	Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin
EP3330260A1 (en)	2016-12-01	2018-06-06	Enantia, S.L.	Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
CN106946981B (zh) *	2017-03-08	2020-08-21	南京陵瑞医药科技有限公司	一种四肽环氧丙烷衍生物及其制备方法和用途
CN110891964A (zh)	2017-05-10	2020-03-17	循环治疗学公司	靶向α4β7整合素的均环肽
WO2019053611A1 (en)	2017-09-14	2019-03-21	Glaxosmithkline Intellectual Property Development Limited	POLY THERAPY FOR THE TREATMENT OF CANCER
CN113185575B (zh) *	2021-05-11	2022-07-12	四川大学	一种花生抗氧化多肽及其制备方法
WO2023220641A2 (en)	2022-05-11	2023-11-16	Juno Therapeutics, Inc.	Methods and uses related to t cell therapy and production of same
US20250302954A1 (en)	2022-05-11	2025-10-02	Celgene Corporation	Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2024097905A1 (en)	2022-11-02	2024-05-10	Celgene Corporation	Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
EP4685151A1 (en)	2024-07-24	2026-01-28	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Proteasome inhibitor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4733665C2 (en) *	1985-11-07	2002-01-29	Expandable Grafts Partnership	Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
JPH01136498A (ja)	1987-11-21	1989-05-29	Nec Corp	状態監視用情報伝送装置
US5135919A (en) *	1988-01-19	1992-08-04	Children's Medical Center Corporation	Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en) *	1989-04-23	1995-08-15	The Trustees Of The University Of Pennsylvania	Substituted cyclodextrin sulfates and their uses as growth modulating agents
US4990448A (en)	1989-08-04	1991-02-05	Bristol-Myers Company	Bu-4061T
US5071957A (en) *	1989-08-04	1991-12-10	Bristol-Myers Company	Antibiotic BU-4061T
US5376645A (en) *	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) *	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HUT62312A (en)	1990-03-05	1993-04-28	Cephalon Inc	Process for producing chymotrypsin-like proteases and their inhibitors
US5340736A (en)	1991-05-13	1994-08-23	The President & Fellows Of Harvard College	ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
GB9300048D0 (en) *	1993-01-04	1993-03-03	Wellcome Found	Endothelin converting enzyme inhibitors
US5693617A (en)	1994-03-15	1997-12-02	Proscript, Inc.	Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en)	1994-10-28	2000-07-04	Leukosite, Inc.	Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en)	1995-04-12	2002-01-01	President And Fellows Of Harvard College	Lactacystin analogs
WO1998010779A1 (en)	1996-09-13	1998-03-19	New York University	Method for treating parasitic diseases with proteasome inhibitors
EP0932617B1 (en) *	1996-10-18	2002-01-16	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SI0932617T1 (en)	1996-10-18	2002-06-30	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AU729793B2 (en)	1996-12-13	2001-02-08	Zymogenetics Inc.	Compositions and methods for stimulating bone growth
US5874418A (en) *	1997-05-05	1999-02-23	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) *	1997-05-05	2000-04-04	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6133248A (en) *	1997-06-13	2000-10-17	Cydex, Inc.	Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
US6099851A (en) *	1998-06-02	2000-08-08	Weisman; Kenneth M.	Therapeutic uses of leuprolide acetate
US6462019B1 (en) *	1998-07-10	2002-10-08	Osteoscreen, Inc.	Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) *	1998-07-10	2005-01-04	Osteoscreen Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) *	1998-07-10	2005-06-07	Osteoscreen, Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en) *	1998-08-07	2001-03-20	Universtiy Of Kansas	Water soluble prodrugs of hindered alcohols
WO2000023614A1 (en) *	1998-10-20	2000-04-27	Millennium Pharmaceuticals, Inc.	Method for monitoring proteasome inhibitor drug action
US6492333B1 (en)	1999-04-09	2002-12-10	Osteoscreen, Inc.	Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) *	1999-05-12	2004-12-14	Yale University	Enzyme inhibition
JP2003528039A (ja) *	1999-10-20	2003-09-24	オステオスクリーン，インコーポレイテッド	骨および毛成長を刺激するためのプロテアソーム活性のインヒビター
EP1430903A1 (de) *	2000-10-12	2004-06-23	Viromics Gmbh	Verwendung von Proteasome Hemmern zur Behandlung von Virus-Infektionen
JP4412586B2 (ja) *	2002-01-08	2010-02-10	エーザイ・アール・アンド・ディー・マネジメント株式会社	エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
EP1496916A2 (en) *	2002-04-09	2005-01-19	Greenville Hospital System	Metastasis modulating activity of highly sulfated oligosaccharides
US20030224469A1 (en) *	2002-06-03	2003-12-04	Buchholz Tonia J.	Methods and kits for assays utilizing fluorescence polarization
US8198270B2 (en) *	2004-04-15	2012-06-12	Onyx Therapeutics, Inc.	Compounds for proteasome enzyme inhibition
US7232818B2 (en) *	2004-04-15	2007-06-19	Proteolix, Inc.	Compounds for enzyme inhibition
AU2005238445B2 (en)	2004-04-15	2012-05-03	Onyx Therapeutics, Inc.	Compounds for enzyme inhibition
AU2005243140A1 (en) *	2004-05-10	2005-11-24	Proteolix, Inc.	Synthesis of amino acid keto-epoxides
JP5108509B2 (ja)	2004-05-10	2012-12-26	プロテオリックス，インコーポレイテッド	酵素阻害のための化合物
AU2005295183A1 (en)	2004-10-20	2006-04-27	CAOnyx Therapeutics, Inc.	Labeled compounds for proteasome inhibition
AU2005313975B2 (en) *	2004-12-07	2012-09-06	Onyx Therapeutics, Inc.	Composition for proteasome inhibition
WO2006099261A2 (en)	2005-03-11	2006-09-21	The University Of North Carolina At Chapel Hill	Potent and specific immunoproteasome inhibitors
JP5436860B2 (ja)	2005-11-09	2014-03-05	オニキスセラピューティクス，インク．	酵素阻害のための化合物
AR057227A1 (es)	2005-12-09	2007-11-21	Centocor Inc	Metodo para usar antagonistas de il6 con inhibidores del proteasoma
DE102006026464A1 (de) *	2006-06-01	2007-12-06	Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma	Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
WO2007149512A2 (en) *	2006-06-19	2007-12-27	Proteolix, Inc.	Peptide epoxyketones for pr0teas0me inhibition
JP4325683B2 (ja) *	2007-02-14	2009-09-02	セイコーエプソン株式会社	画像表示装置、及び画像表示装置の制御方法
WO2008140782A2 (en)	2007-05-10	2008-11-20	Proteolix, Inc.	Compounds for enzyme inhibition
MY173938A (en)	2007-10-04	2020-02-27	Onyx Therapeutics Inc	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2009308516B2 (en)	2008-10-21	2016-08-25	Onyx Therapeutics, Inc.	Combination therapy with peptide epoxyketones

2005
- 2005-04-14 AU AU2005238445A patent/AU2005238445B2/en not_active Expired
- 2005-04-14 DK DK05735686.7T patent/DK1745064T3/da active
- 2005-04-14 CN CN201310512372.8A patent/CN103554222A/zh active Pending
- 2005-04-14 PT PT05735686T patent/PT1745064E/pt unknown
- 2005-04-14 SG SG200902548-7A patent/SG152239A1/en unknown
- 2005-04-14 US US11/578,626 patent/US8129346B2/en active Active
- 2005-04-14 AT AT05735686T patent/ATE494298T1/de active
- 2005-04-14 DE DE602005025750T patent/DE602005025750D1/de not_active Expired - Lifetime
- 2005-04-14 EP EP05735686A patent/EP1745064B1/en not_active Expired - Lifetime
- 2005-04-14 PL PL05735686T patent/PL1745064T3/pl unknown
- 2005-04-14 JP JP2007508543A patent/JP5616569B2/ja not_active Expired - Lifetime
- 2005-04-14 CA CA002562411A patent/CA2562411A1/en not_active Abandoned
- 2005-04-14 CN CN201110037869XA patent/CN102174076A/zh active Pending
- 2005-04-14 WO PCT/US2005/012740 patent/WO2005105827A2/en not_active Ceased
- 2005-04-14 SG SG2012076659A patent/SG185306A1/en unknown
- 2005-04-14 BR BRPI0509879-3A patent/BRPI0509879A/pt not_active Application Discontinuation
2006
- 2006-09-28 IL IL178400A patent/IL178400A/en active IP Right Grant
2011
- 2011-02-18 CY CY20111100205T patent/CY1117244T1/el unknown
- 2011-09-12 JP JP2011198810A patent/JP2012041346A/ja active Pending
- 2011-12-22 US US13/334,263 patent/US8207124B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,288 patent/US8207125B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,466 patent/US8207126B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,372 patent/US8324174B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,544 patent/US8207127B2/en not_active Expired - Lifetime
- 2011-12-22 US US13/334,469 patent/US8207297B2/en not_active Expired - Lifetime
- 2011-12-26 IL IL217210A patent/IL217210A0/en unknown
- 2011-12-26 IL IL217211A patent/IL217211A0/en unknown
2012
- 2012-03-02 US US13/411,044 patent/US20120277146A1/en not_active Abandoned
2013
- 2013-03-12 US US13/797,740 patent/US20130324459A1/en not_active Abandoned
- 2013-08-05 JP JP2013162017A patent/JP2014012676A/ja active Pending
2016
- 2016-04-21 BE BE2016C014C patent/BE2016C014I2/fr unknown

Also Published As

Publication number	Publication date
EP1745064A2 (en)	2007-01-24
IL178400A0 (en)	2007-02-11
JP2014012676A (ja)	2014-01-23
IL217210A0 (en)	2012-01-31
US20120277146A1 (en)	2012-11-01
SG152239A1 (en)	2009-05-29
CN103554222A (zh)	2014-02-05
WO2005105827A2 (en)	2005-11-10
HK1097860A1 (zh)	2007-07-06
US20120094926A1 (en)	2012-04-19
US8324174B2 (en)	2012-12-04
US8129346B2 (en)	2012-03-06
IL178400A (en)	2012-02-29
CN102174076A (zh)	2011-09-07
US8207297B2 (en)	2012-06-26
DE602005025750D1 (de)	2011-02-17
US8207125B2 (en)	2012-06-26
US8207124B2 (en)	2012-06-26
JP2008501637A (ja)	2008-01-24
IL217211A0 (en)	2012-01-31
US20120094929A1 (en)	2012-04-19
US20120094930A1 (en)	2012-04-19
JP2012041346A (ja)	2012-03-01
JP5616569B2 (ja)	2014-10-29
PL1745064T3 (pl)	2011-06-30
US8207126B2 (en)	2012-06-26
BRPI0509879A (pt)	2007-10-16
EP1745064B1 (en)	2011-01-05
US20120101048A1 (en)	2012-04-26
ATE494298T1 (de)	2011-01-15
CA2562411A1 (en)	2005-11-10
AU2005238445A1 (en)	2005-11-10
DK1745064T3 (da)	2011-04-11
US20080200398A1 (en)	2008-08-21
WO2005105827A3 (en)	2006-03-30
CY1117244T1 (el)	2017-04-05
US8207127B2 (en)	2012-06-26
SG185306A1 (en)	2012-11-29
US20120101050A1 (en)	2012-04-26
PT1745064E (pt)	2011-03-23
US20130324459A1 (en)	2013-12-05
AU2005238445B2 (en)	2012-05-03
US20120094928A1 (en)	2012-04-19

Publication	Publication Date	Title
BE2024C508I2 (zh)	2024-08-08
BE2023C542I2 (zh)	2025-02-07
BE2022C549I2 (zh)	2024-08-08
BE2021C001I2 (zh)	2025-02-11
BE2020C513I2 (zh)	2024-08-08
BE2020C517I2 (zh)	2024-08-08
BE2019C540I2 (zh)	2024-08-08
BE2019C523I2 (zh)	2025-02-10
BE2019C506I2 (zh)	2025-04-23
BE2018C045I2 (zh)	2024-08-08
BE2020C525I2 (zh)	2025-02-11
BE2017C063I2 (zh)	2025-02-07
BE2017C027I2 (zh)	2024-08-08
BE2017C023I2 (zh)	2024-08-08
BE2017C002I2 (zh)	2024-08-08
BE2016C067I2 (zh)	2024-08-08
BE2016C014I2 (zh)	2024-10-09
BE2015C041I2 (zh)	2024-10-08
BE2015C038I2 (zh)	2019-10-23
BE2015C014I2 (zh)	2024-08-08
BE2014C071I2 (zh)	2024-10-08
BE2015C015I2 (zh)	2025-04-29
BE2014C064I2 (zh)	2024-08-08
BE2014C063I2 (zh)	2024-08-08
BE2014C010I2 (zh)	2024-08-08